Ixazomib Approved by FDA for Multiple Myeloma Treatment

Farydak (panobinostat) now FDA-approved for multiple myeloma
Farydak (panobinostat) now FDA-approved for multiple myeloma

(HealthDay News) -- Ninlaro (ixazomib), in combination with two other drugs, has been approved by the U.S. Food and Drug Administration to treat patients with multiple myeloma who have had at least one prior treatment with a different therapy.

Ninlaro, a proteasome inhibitor, is designed to block enzymes that spur the growth and survival of multiple myeloma cells, the FDA said Friday in a news release. Ninlaro is approved in combination with another multiple myeloma drug, Revlimid (lenalidomide), and the corticosteroid drug dexamethasone.

The drug combination was evaluated in clinical studies involving 722 patients. Those who took Ninlaro in tandem with the other two drugs lived for more than 20 months without their disease progressing, compared with about 14 months among those who took a placebo and the other two drugs, the FDA said. Side effects of Ninlaro included diarrhea, constipation, thrombocytopenia, peripheral neuropathy, nausea/vomiting, and back pain.

"Today's approval is the third drug for multiple myeloma approved this year and provides patients with a new oral treatment that slows disease progression when other therapy has failed," Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, said in a statement.

Ninlaro is produced by the Japanese drug maker Takeda Pharmaceuticals.

More Information

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs